These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30822348)

  • 1. Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort.
    Gomides APM; de Albuquerque CP; Santos ABV; Amorim RBC; Bértolo MB; Júnior PL; Santos IA; Giorgi RDN; Sacilotto NC; Radominski SC; Borghi FM; Guimarães MFBR; Pinto MRDC; Resende GG; Bonfiglioli KR; Silva HCD; Sauma MFLDC; Sauma ML; de Medeiros JB; Pereira IA; de Castro GRW; Brenol CV; Xavier RM; da Mota LMH; Pinheiro GDRC
    PLoS One; 2019; 14(3):e0213219. PubMed ID: 30822348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
    Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
    Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs 'in' rheumatoid arthritis.
    Gomides APM; de Albuquerque CP; Santos ABV; Bértolo MB; Júnior PL; Giorgi RDN; Radominski SC; Resende Guimarães MFB; Bonfiglioli KR; de Fátima Lobato da Cunha Sauma M; Pereira IA; Brenol CV; da Mota LMH; Pinheiro GDRC
    Int J Clin Pharm; 2021 Jun; 43(3):737-742. PubMed ID: 33085040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy.
    Conigliaro P; D'Antonio A; D'Erme L; Lavinia Fonti G; Triggianese P; Bergamini A; Chimenti MS
    PLoS One; 2023; 18(2):e0281213. PubMed ID: 36730337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
    Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide.
    Kwon OC; Oh JS; Hong S; Lee CK; Yoo B; Kim YG
    Clin Exp Rheumatol; 2019; 37(5):813-819. PubMed ID: 30767868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study.
    Gomides APM; de Albuquerque CP; Santos ABV; Bértolo MB; Júnior PL; Giorgi RDN; Radominski SC; Resende Guimarães MFB; Bonfiglioli KR; de Fátima Lobato da Cunha Sauma M; Pereira IA; Brenol CV; da Mota LMH; da Rocha Castelar Pinheiro G
    Adv Rheumatol; 2020 Feb; 60(1):16. PubMed ID: 32106881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG; den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
    Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG
    Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.
    Kaltsonoudis E; Pelechas E; Voulgari PV; Drosos AA
    Semin Arthritis Rheum; 2019 Feb; 48(4):597-602. PubMed ID: 30075990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China.
    Sun J; Dai S; Zhang L; Feng Y; Yu X; Zhang Z
    Clin Rheumatol; 2021 May; 40(5):1789-1798. PubMed ID: 33058034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).
    Pope JE; Rampakakis E; Movahedi M; Cesta A; Li X; Couto S; Sampalis JS; Bombardier C;
    Clin Exp Rheumatol; 2018; 36(2):215-222. PubMed ID: 29148403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment.
    Drosos AA; Pelechas E; Kaltsonoudis E; Voulgari PV
    Curr Rheumatol Rep; 2020 Jun; 22(8):44. PubMed ID: 32591916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study.
    Xie W; Huang H; Zhang Z
    Intern Emerg Med; 2023 Sep; 18(6):1759-1767. PubMed ID: 37418144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in non-biological drugs for the treatment of rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Opin Pharmacother; 2024; 25(1):45-53. PubMed ID: 38126739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.